Proteasome inhibitors as experimental therapeutics of autoimmune diseases

Current treatment strategies for rheumatoid arthritis (RA) consisting of disease-modifying anti-rheumatic drugs or biological agents are not always effective, hence driving the demand for new experimental therapeutics. The antiproliferative capacity of proteasome inhibitors (PIs) has received consid...

Full description

Saved in:

Bibliographic Details
Published in:	Arthritis research & therapy Vol. 17; no. 1; p. 17
Main Authors:	Verbrugge, Sue Ellen, Scheper, Rik J, Lems, Willem F, de Gruijl, Tanja D, Jansen, Gerrit
Format:	Journal Article
Language:	English
Published:	London BioMed Central 28.01.2015 BioMed Central Ltd
Subjects:	Antigen presenting cells Antigens Antirheumatic agents Arthritis, Rheumatoid - drug therapy Autoimmune Diseases - drug therapy Development and progression Drug therapy Health aspects Homeopathy Humans Interleukins Materia medica and therapeutics Medicine Medicine & Public Health Orthopedics Physiological aspects Proteasome Endopeptidase Complex - adverse effects Proteasome Inhibitors - therapeutic use Review Rheumatoid factor Rheumatology Systemic lupus erythematosus T cells Therapeutics Systemic Lupus Erythematosus Major Histocompatibility Complex Class Immune Effector Cell Bortezomib Rheumatoid Arthritis
ISSN:	1478-6354, 1478-6362, 1478-6354, 1478-6362
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!